Evidence map›Paper›PMID 31076942›Full record

Trial reportClinical rheumatology2019

Influence of different supplementation on platelet aggregation in patients with rheumatoid arthritis.

Marijana Tomic-Smiljanic, Dragan Vasiljevic, Aleksandra Lucic-Tomic, Nebojsa Andjelkovic, Vladimir Jakovljevic, Sergey Bolovich, Mirjana Veselinovic

Abstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Clinical rheumatology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Marijana Tomic-SmiljanicPublic Health Center, DZ Rakovica, 22 Kraljice Jelene, 11000, Belgrade, Serbia.
Dragan VasiljevicFaculty of Medical Sciences, Department of Hygiene and Ecology, University of Kragujevac, 69 Svetozara Markovica, 34000, Kragujevac, Serbia.
Aleksandra Lucic-TomicFaculty of Medical Sciences, Department of Internal medicine, University of Kragujevac, 69 Svetozara Markovica, 34000, Kragujevac, Serbia.
Nebojsa AndjelkovicFaculty of Medical Sciences, Department of Internal medicine, University of Kragujevac, 69 Svetozara Markovica, 34000, Kragujevac, Serbia.
Vladimir JakovljevicFaculty of Medical Sciences, Department of Physiology, University of Kragujevac, 69 Svetozara Markovica, 34000, Kragujevac, Serbia.
Sergey BolovichDepartment of Human Pathology, 1st Moscow State Medical, University IM Sechenov, Trubetskaya Street 8, Str. 2, Moscow, Russia, 119991.
Mirjana VeselinovicFaculty of Medical Sciences, Department of Internal medicine, University of Kragujevac, 69 Svetozara Markovica, 34000, Kragujevac, Serbia. veselinovic.m@sbb.rs.ORCID http://orcid.org/0000-0001-7586-7440
University of Kragujevac · RSInstitute of Public Health of Serbia · RSSechenov University · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionLong-chain n-3 polyunsaturated fatty acids (n-3 PUFAs; eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA)) have been reported to reduce platelet aggregation. Our aim was to prospectively assess the potential influence of different supplementation omega-3 PUFA on the antiplatelet effects in rheumatoid arthritis (RA) patients.

methodsThe study included 60 patients with RA at the Department of Rheumatology, Clinical Center Kragujevac. Patients were divided into three groups depending on who used concentrated fish oil only or concentrated fish oil in combination with evening primrose oil or control group without supplementation in a period of 3 months. Platelet aggregation was measured using the multiplate analyzer and expressed through the value of adenosine diphosphate (ADP) test, aranchidonic acid-induced aggregation (ASPI) test, thrombin receptor-activating peptide (TRAP) test (to assess baseline platelet aggregation), and the ratio of ADP/TRAP and ASPI/TRAP representing the degree of inhibition of platelet aggregation compared to the basal value. The platelet function analysis in whole blood was performed 18-24 h before starting supplementation and after 90 days. Considerations were taken in the representation of demographic, clinical characteristics, and laboratory parameters between the groups.

resultsPatients who used concentrated fish oil only had a significantly lower value of the ratio of ADP/TRAP (0.68 ± 0.20) compared to patients without supplementation (0.83 ± 0.12; p = 0.008), while there was no statistically significant difference in values of other laboratory parameters of platelet function between other groups.

conclusionsCo-administration of supplementation-concentrated fish oil may reduce platelet aggregation in adults with RA. KEY POINTS: • Omega-3 PUFAs are essential for health and are known to possess anti-inflammatory properties, improving cardiovascular health as well as benefiting inflammatory diseases.. • In this paper, we report on anti-aggregation effects n-3 PUFAs and ɤ-linolenic acid in RA. • The risk of cardiovascular morbidity and mortality is increased in RA, and dietary supplementation of n-3 PUFA may have preventive potential for the cardiovascular management in rheumatoid arthritis.

Indexed as

Dietary SupplementsAgedArthritis, RheumatoidFemaleFish Oilsgamma-Linolenic AcidHumansLinoleic AcidsMiddle AgedOenothera biennisPlant OilsPlatelet AggregationPlatelet Function Testsevening primrose oilFish Oilsgamma-Linolenic AcidLinoleic AcidsPlant OilsFatty acidsPlatelet aggregationRheumatoid arthritis

Identifiers

PMID31076942
OpenAlexW2944744520

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.